Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to notice the effects of Wegovy within the first one to four weeks, though what those effects look like varies considerably from person to person. The earliest sign is usually a quieter appetite, not dramatic weight loss. Meaningful scale movement tends to follow over subsequent months, as semaglutide builds in your system and your dose is titrated upward by your prescriber. These are prescription-only medicines that require a clinical assessment before they can be supplied.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The question most people are sitting with when they search this is simpler than it sounds: should I keep going, or is something wrong? That is a reasonable thing to wonder. Wegovy's mechanism (slowing gastric emptying and acting on GLP-1 receptors to reduce appetite and caloric intake) does not switch on like a light. It accumulates. So the honest answer is that the first four weeks are rarely about the number on the scales.
What typically arrives early is a shift in hunger signals. Meals feel filling sooner. The urge to snack between them dulls. Some people describe it as the food noise quietening. That is semaglutide doing exactly what it is licensed to do, even if the tape measure has not moved yet. The Wegovy overview page explains the mechanism in more detail if you want the pharmacology behind it.
Weight loss becomes more measurable from around weeks four to eight, and tends to accelerate once the dose steps up. The STEP 1 trial, which the NHS semaglutide medicines page references in its efficacy summary, recorded roughly 15% average weight reduction over 68 weeks, the bulk of that coming after the starter and mid-range doses were left behind.
The 0.25 mg starting dose serves one purpose: settling your digestive system into the medicine. It is not a therapeutic dose in the weight-loss sense. Nausea, loose stools, or reflux are common early on (particularly in the first days after a dose increase) and these GI effects are precisely why the titration schedule exists. Rushing it does not produce faster results; it produces more side effects and more reasons to stop.
For most people, the stomach settles within one to two weeks at each dose level. By the time the 1.0 mg or 1.7 mg doses are reached, appetite suppression tends to be noticeably stronger, and weight loss becomes more consistent week to week. Full maintenance at 2.4 mg (or 7.2 mg, which the MHRA approved in April 2026 for eligible patients) is where the trial data's headline figures come from, and getting there typically takes five months of careful stepping.
If you are weighing up how this compares across the semaglutide class more broadly, our page on how long semaglutide takes to take effect covers the shared mechanism and where the timelines diverge between different formulations.
Biology, not effort, explains most of the variation between individuals. Starting BMI matters: people with a higher starting weight often see larger absolute losses but similar percentage losses. Diet composition influences how hard the medicine has to work, high-calorie, low-protein eating patterns blunt the appetite effect. Activity levels shape body composition as weight falls, even if the scales move at the same pace.
GI tolerability is the factor most within reach. People who push fluids, keep meals smaller and protein-forward, and avoid fatty or very spicy foods during a dose increase tend to tolerate steps better, and tolerating steps is what gets you to a maintenance dose, which is where the meaningful results live.
The cost of the treatment is a practical consideration too, and the context around Wegovy pricing in the UK is worth understanding before you commit. Some people also ask whether Wegovy can produce results without structured exercise, there is more to that question than a simple yes or no, and our page on Wegovy and weight loss without exercise goes through the evidence honestly.
NICE's guidance (TA875) includes a clinical checkpoint: if you have lost less than 5% of your starting body weight after six months on your maintenance dose, your prescriber should review whether continuing makes sense for you. That is not a failure threshold, it is a built-in clinical gate designed to make sure the medicine is actually serving you.
Short of that, slow early progress is normal and not a reason to increase the dose yourself or switch products without advice. A prescriber's job at each repeat review is to weigh up exactly these questions: is the titration on track, are side effects manageable, and is the direction of travel right? At nume, a real clinician reviews every repeat order before it is dispensed, your case is read by a person, not processed automatically. If that kind of ongoing clinical oversight matters to you, starting a free consultation is the straightforward next step.
For a closer look at how the timeline compares week by week, see how long Wegovy takes to work and when Wegovy starts taking effect.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.